How This Evidence Evolved
Sudden Hearing Loss Steroid Treatment
From no standard treatment to oral steroids, intratympanic salvage, and combination therapy
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
PTA gain >15 dB at 4 weeks after the last injection: IT dexamethasone plus high-dose prednisone taper vs taper alone (higher proportion with combination, p<0.02)
Hearing recovery with salvage steroids after failed traditional therapy (6 RCTs, 283 subjects): salvage steroids vs control (odds ratio 6.04, 95% CI 3.26-11.2; poor-quality trials); steroid vs placebo, odds ratio 1.52 (95% CI 0.83-2.77)
Hearing gain >30 dB at a minimum 1-month follow-up in oral-steroid non-responders: weekly IT dexamethasone for 3 weeks vs control 8/15 (53.3%) vs 1/14 (7.1%); mean gain 28.4 vs 13.2 dB (P<.05)
Significant hearing recovery 3 months after treatment: systemic prednisolone plus 3 IT dexamethasone injections vs prednisolone alone 31/46 (67.39%) vs 24/46 (52.17%); median PTA gain 23.12 vs 16.87 dB (between-group differences not significant, p=0.10 and p=0.13)
Integration into clinical practice guidelines and recommendations
Corticosteroids may be offered as initial therapy within 2 weeks of symptom onset (Option, KAS 8); offer, or refer for, intratympanic steroid therapy when recovery is incomplete 2 to 6 weeks after onset (Recommendation, KAS 10); evaluate for retrocochlear pathology with MRI or auditory brainstem response (Recommendation, KAS 6)
Current standard of care and ongoing research directions
Landmark Trials in This Story
The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study
Hearing recovery
Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial
Change in pure tone average at 2 months
Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss
PTA gain >15 dB at 4 weeks after the last injection: IT dexamethasone plus high-dose prednisone taper vs taper alone (higher proportion with combination, p<0.02)
Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials.
Hearing recovery with salvage steroids after failed traditional therapy (6 RCTs, 283 subjects): salvage steroids vs control (odds ratio 6.04, 95% CI 3.26-11.2; poor-quality trials); steroid vs placebo, odds ratio 1.52 (95% CI 0.83-2.77)
Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment.
Hearing gain >30 dB at a minimum 1-month follow-up in oral-steroid non-responders: weekly IT dexamethasone for 3 weeks vs control 8/15 (53.3%) vs 1/14 (7.1%); mean gain 28.4 vs 13.2 dB (P<.05)
Intratympanic and systemic steroids for sudden hearing loss.
Significant hearing recovery 3 months after treatment: systemic prednisolone plus 3 IT dexamethasone injections vs prednisolone alone 31/46 (67.39%) vs 24/46 (52.17%); median PTA gain 23.12 vs 16.87 dB (between-group differences not significant, p=0.10 and p=0.13)
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.